Introduction
In the current era, primary percutaneous coronary intervention (PCI) remains the gold standard for prompt reperfusion of the occluded blood vessel, salvaging the myocardium, reducing the infarct size, and prolonging life, 1, 2 following an acute ST-elevation myocardial infarction (AMI). However, delivering a primary PCI service globally conforming to timings stipulated in guidelines is not always feasible owing to geographical and other logistic issues. In these situations, fibrinolytic therapy still continues to remain the main stay of immediate coronary reperfusion. In the late 1980s and early 1990s, a meta-analysis of the addition of various other strategies of either early or delayed PCI to lysis showed no convincing clinical benefit. 3 The addition of a thienopyridine to aspirin and fibrinolytic drugs also results in improved infarct artery patency 4 and mortality. With these evolving pharmacotherapies as an adjunct to fibrinolysis, which is more readily available, the subsequent role of a routine early PCI in the first 24 hours vs. ischaemia-guided PCI remains debatable. We have performed an up-to-date meta-analysis of randomized controlled trials including recent studies that adopt this routine early invasive strategy, to establish an evidence-based practice.
Methods
This study was performed according to the meta-analysis of observational studies in epidemiology (MOOSE) and guidelines for preferred reporting items for systematic reviews and meta-analyses (PRISMA). 6, 7 A MEDLINE search (1977 to May 2010) was performed using the search terms 'coronary, thrombolysis, early or immediate stenting, and acute ST-elevation myocardial infarction'. References and review articles obtained in this manner as well as from global cardiovascular scientific sessions/congresses were further scrutinized to ensure that all relevant studies were identified ( Figure 1 ).
Only randomized controlled studies comparing early routine with ischaemia-guided PCI were included, and meta-analysis was performed using a random effects model. A primary composite endpoint of allcause mortality, re-infarction, and ischaemia at 30 days was studied. A further separate analysis of the individual relative risk of mortality, re-infarction, and ischaemia was made and safety assessed from major bleeding as determined from the odds ratio (OR).
Statistical analysis
All trials included in this meta-analysis were prospective, randomized control trials, and publication level data were used for the current analysis. For individual trials, the x 2 heterogeneity test was used to calculate the significance, OR, and 95% confidence intervals (CIs) for the differences in outcome between the ischaemia-guided arm and the early PCI arm in patients post-AMI. Baseline characteristics were evenly distributed between the two treatment groups in all trials. The actual treatment received was clearly shown for all trials, and the analysis was performed on the basis of the intention-to-treat. We used the Cochran Q-test to assess heterogeneity across trials. Also, we calculated the I 2 statistic to measure the consistency between trials with values of 25, 50, and 75% defining the cut-off points for identifying low, moderate, and high degrees of heterogeneity, respectively. 8 Treatment effects from individual trials were pooled using the random effects DerSimonian and Laird model. 9 Data were analysed using Comprehensive Meta-Analysis (Version 2.0, Engelwood, NJ, USA). The likelihood of publication or 'small study' bias was assessed graphically by generating a funnel plot for the primary endpoint of MACE and by means of Egger's test (risk of bias tables was constructed by application of the six criteria of the Cochrane collaborative to assess the potential for bias (http://www.cochrane.org/) by two of the authors independently (S.P.D. and M.A.M.)).
Results
A total of eight trials identified dating back to 1977 fulfilled the search criterion, PRAGUE,
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SIAM III, 11, 12 GRACIA-I, 13 CAPITAL-AMI, 14 CARESS-in-AMI, 15, 16 WEST, 17 TRANSFER-AMI, 18 and NORDISTEMI, 19 and a total of 3195 patients were studied. Definition criteria of re-infarction, ischaemia, indications for angiography in ischaemia-guided arm, and major bleeds used in the trials are shown in Table 1 . Baseline characteristics were well balanced between the groups and fulfilled criterion stipulated in the studies ( Table 2 ). The major differences between the studies included differences in inclusion criterion, such as time of symptom onset till presentation. This time duration varied from at least 20 min in the WEST study and up to 12 h in the TRANSFER-AMI, CARESS-AMI, GRACIA-I, and In first 18 h enzyme criteria not used
Continued SIAM III studies. Patients with cardiogenic shock and a contraindication for thrombolysis were excluded in most studies. All studies used aspirin of at least 250 mg, along with clopidogrel 300 mg or ticlopidine 500 mg as pharmacotherapy adjuncts. Thrombolytic therapy consisted of tenecteplase (TNK) and unfractionated or low-molecular-weight heparin in the NORDISTEMI, TRANSFER-AMI, WEST, and CAPITAL-AMI studies. Thrombolysis with recombinant human-tissue plasminogen activator (rt-PA) was performed in the SIAM III and CARESS-AMI (half-dose rt-PA) studies along with unfractionated heparin. Streptokinase was used in the protocol in the PRAGUE-I study along with low-molecular-weight heparin. Glycoprotein IIb/IIIa inhibitors were not used in the protocol in the CAPITAL-AMI and PRAGUE-I studies, but their use was a standard adjunct to the interventional procedure in the CARESS-AMI study and optional in the other study protocols including NORDIS-TEMI 14%, TRANSFER-AMI 82%, and WEST 48%. Time from lysis to routine early PCI varied from a median of 2.7 h in the NORDISTEMI study to under 24 h in the WEST and GRACIA-I studies. A risk of bias analysis in which articles are judged by a set of six criteria defined by the Cochrane collaborative to assess for bias (http://www.cochrane.org/) is presented in Table 3 .
The combined endpoint of 30-day mortality, re-infarction, and ischaemia was reached in 106/1487 (7.3%) patients in the routine early PCI group and 199/1470 (13.5%) patients in the ischaemiaguided PCI group following lysis. Meta-analysis of these data demonstrated an OR of 0.47 (95% CI, 0.34-0.65, P , 0.0001; Q ¼ 8.6, P ¼ 0.197; I 2 ¼ 30%) in favour of a routine early PCI strategy ( Figure 2) . A funnel plot of studies included in the meta-analysis of 30-day MACE data to assess for publication bias is presented in Figure 3 . Studies are symmetrically distributed indicating the absence of publication bias, confirmed by means of a negative Egger's test (P ¼ 0.28). Exploratory meta-regression analyses were performed to appraise the impact of moderator or covariates on the MACE associated with an early PCI strategy. We did not find a statistically significant association between time to PCI (P ¼ 0.17) and year of publication (P ¼ 0.31) on MACE outcomes. The observed reduction in OR for MACE appears to be driven by significant reduction both in the re-infarction rates with an OR of 0.62 (95% CI, 0.42-0.90, P , 0.05; Q ¼ 2.32, P ¼ 0.94; I 2 ¼ 0%) and in ischaemia with an OR of 0.21 (95% CI, 0.10-0.47, P , 0.001; Q ¼ 14.7, P , 0.05; I 2 ¼ 59.2%) in the routine early PCI group following lysis (Figures 4 and 5) . There was no difference in the risk of major bleeding during the index admission and up to 30 days in the two strategies with an OR of 0.96 (95% CI, 0.65 -1.44, P ¼ 0.86; Q ¼ 2.73, P ¼ 0.838; I 2 ¼ 0%), as shown in Figure 6 . The 30-day mortality rates were not different between the two groups with an OR of 0.87 (95% CI, 0.60 -1.24, P ¼ 0.43; Q ¼ 4.71, P ¼ 0.69; I 2 ¼ 0%) calculated, as presented in Figure 7 . Six-month data were available from only three of the trials (SIAM III, CAPITAL, and TRANSFER). The combined endpoint of mortality, ischaemia, and re-infarction was reached in 78/768 (10.6%) patients in the routine early PCI group and 128/765 (16.73%) patients in the ischaemia-guided PCI group following lysis. Again, there appeared to be continued benefits in the routine early PCI group with an OR of 0.33 (95% CI, 0.20-0.53; P , 0.0001). This is again driven by significantly lower re-infarction rates with an OR of 0.56 (95% CI, 0.35-0.89; P , 0.05) and again no significant mortality difference with an OR of 0.73 (95% CI, 0.47 -1.154; P ¼ 0.18). 
Discussion
Primary PCI remains the gold standard in the management of acute ST-elevation myocardial infarction, but this needs to be performed by an experienced team. Again this benefit, being time-dependent, can be lost if call-to-balloon time is in excess of 90 -120 min as stipulated in the American and European guidelines. 1, 2 Although all effort has to be made to provide a primary PCI service, this may not be logistically achievable in centres world-wide, particularly when there are long transfer times. In these situations, thrombolysis continues to remain the standard management. Previous studies showed that addition of thienopyridines as an adjunct to PCI has reduced the incidence of abrupt vessel closure after PCI.
4,20
Benefits of an early PCI strategy have been evaluated by Wijeysundera et al. 21 in an earlier meta-analysis of five trials randomizing 1235 patients with significant reductions of death and re-infarction in the early intervention group with no increase in stroke or major bleed. However, since then, three large trials-TRANSFER-AMI, 18 CARESS-AMI, 15, 16 and NORDISTEMI 19 incorporating similar strategies in over 1900 patients-have been published and long-term data are also now being generated in the process. Our meta-analysis has assessed the efficacy and safety of early PCI following lysis after acute ST-elevation myocardial infarction in the context of today's potent pharmacoinvasive therapy and modern day stent manufacturing technology and deployment methodology. It appears that the strategy of routine early PCI within the first 24 h of lysis is beneficial over the ischaemia-guided strategy with significant reduction in the primary composite endpoint of mortality, re-infarction, and ischaemia. This reduction appeared to be mainly driven by the reduction in re-infarction rates and ischaemia. Early PCI is not associated with increase in major bleeding as was seen in previous trials, and mortality rates were not different. Furthermore, follow-up data at 6 months demonstrate continued benefit from immediate PCI driven by a reduction in re-infarction. These numbers are small and unlikely to determine clinical significance. However, a perseverance of this trend will dictate a change in clinical practice in favour of routine early PCI following lysis as an alternative to primary PCI, especially where facilities fall short or as an interim measure while setting up a primary PCI service.
At 1-year follow-up in the CARESS-AMI study, a non-significant reduction in the composite endpoint of death, re-infarction, and ischaemia occurred in 11.4% of patients in the early PCI group and 16.4% in the ischaemia-guided PCI group (P ¼ 0.07) driven by a persistently lower incidence of refractory ischaemia in the early PCI group (3.4 vs. 8.7%; P , 0.01). 16 Mortality rates were virtually identical, suggesting attenuation of the early benefit of a 'pharmacoinvasive' approach. Further, in the GRACIA-I study follow-up of patients at 1 year, the early PCI group also showed lower frequency of the primary composite endpoint in 9% of the patients (vs. 21% in the ischaemia-guided PCI group) and with hazard ratio (HR) 0.44 (95% CI, 0.28 -0.70; P ¼ 0.0008) and Figure 4 Thirty-day re-infarction rates with odds ratio favouring the routine early percutaneous coronary intervention following lysis (P , 0.011, significant). Figure 3 Funnel plot of studies for 30-day MACE data.
Routine early coronary angioplasty vs. ischaemia-guided angioplasty statistically non-significant decrease in the rate of death or re-infarction [7 vs . 12%, HR 0.59 (0.33-1.05), P ¼ 0.07]. 13 Early PCI reduced ischaemia-induced re-admission to hospital and revascularization. In the NORDISTEMI study, although there was no significant difference when an endpoint of ischaemia was added to the composite of death, re-infarction, and stroke at 12 months with early intervention (20.9 vs. 27.3%, HR 0.72, P ¼ 0.18), this appeared significant for the composite of death, Figure 6 Thirty-day major bleeding rates with odds ratio showing no increased risk with early percutaneous coronary intervention following lysis group (P ¼ 0.857, not significant).
Figure 5
Thirty-day ischaemia rates with odds ratio favouring the routine early percutaneous coronary intervention following lysis (P , 0.001, significant).
re-infarction, and stroke (6.0 vs. 15.9%, HR 0.36, P ¼ 0.01), suggesting that an early invasive strategy may be the preferred option following thrombolysis. In the SIAM III study, early PCI strategy patients with successful or failed reperfusion after lysis within 6 h showed similar outcomes and had a significant improvement in their left ventricular function, which even improved further in the 6 months of follow-up. 11 Investigators presented their long term-data (6.9 + 2.9 years) at the TCT 2008. Early PCI continued to maintain a significant reduction in the combined endpoint of death, re-infarction, and target lesion revascularization (42.7 vs. 64.2%; P ¼ 0.005) and is associated with significantly higher survival (mortality 14.6 vs. 27.2%; P ¼ 0.037).
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There was no significant difference in stroke or major bleeding between the two strategies. Currently, indication for adjunctive PCI within 3 -24 h following successful lysis has a class IIa, level of evidence A recommendation. Although a lack of 30-day mortality benefit may preclude an upgrade of the guidelines, survival figures from long-term studies appear encouraging enough to promulgate a change.
Our meta-analysis has a number of potential limitations. An inherent limitation of any meta-analysis is that of publication bias; studies that show a neutral outcome in mortality are less likely to be published than those that show a positive outcome and thus tend to bias any meta-analysis of published data towards a more positive outcome. However, our analysis for publication bias has not demonstrated the presence of this potential confounder. Pharmacotherapies with thrombolytic agents used in the studies are all licensed fibrinolytic agents, but a non-fibrin-specific lytic role cannot be excluded. Furthermore, there was a significant variance in the time of lysis to early PCI between studies, for example, the CAPITAL-AMI study had a median time to early PCI of 1.6 h, whereas GRACIA-I had a mean delay of 16.7 h. Our meta-analysis through meta-regression analysis does not demonstrate that there is a correlation between magnitude of benefit and timing of early PCI strategy within the 24 h window that these studies were performed. However, such an analysis cannot define whether within this window there is a cut-off period during which maximum benefit is achieved. Studies were powered to identify differences in the composite endpoint and not the individual components of mortality, ischaemia, or re-infarction. Larger studies with long-term follow-up will be needed to address these issues.
Conclusion
Globally, where primary PCI is not a feasible option for acute ST-elevation myocardial infarction, our study supports the case for early routine PCI within 24 h of thrombolysis. The major benefit at 30 days is the reduction of the composite of mortality, ischaemia, and re-infarction driven by the reduction in ischaemia and re-infarction events.
